Home › Trials › NCT06247319

Evaluating the effectiveness of risankizumab for moderate plaque psoriasis in Greece

A Non-interventional, Prospective Study to Evaluate the Effectiveness of Risankizumab in Patients With Recent Diagnosis of Moderate Plaque Psoriasis in a Real Life Setting in Greece- the REDEFINE Study

Observational AbbVie · NCT06247319

This study is testing how well risankizumab works for people in Greece with moderate plaque psoriasis who haven't tried advanced treatments yet, to see how it affects their skin and quality of life.

Quick facts

Study typeObservational
Enrollment250 (estimated)
Ages18 Years and up
SexAll
SponsorAbbVie Industry-sponsored
Drugs / interventionsrisankizumab, deucravacitinib
Locations21 sites (Patras, Achaia and 20 other locations)
Trial IDNCT06247319 on ClinicalTrials.gov

What this trial studies

This observational study aims to assess the effectiveness of risankizumab in patients diagnosed with moderate plaque psoriasis within the last 24 months. It focuses on evaluating both clinical parameters and patient-reported outcomes to understand the treatment's impact on quality of life. Participants must be naïve to advanced treatments and have specific severity scores for their psoriasis. The study will gather data in a real-life setting across multiple locations in Greece.

Who should consider this trial

Good fit: Ideal candidates are individuals with a recent diagnosis of moderate plaque psoriasis who have not previously received advanced treatments.

Not a fit: Patients currently undergoing treatment with investigational drugs or those with severe psoriasis may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the effectiveness of risankizumab, potentially improving treatment options for patients with moderate plaque psoriasis.

How similar studies have performed: Other studies evaluating biologic treatments for psoriasis have shown promising results, indicating that this approach is supported by prior successful research.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Participants with a confirmed diagnosis of moderate plaque PsO made by a specialist ≤24 months prior to risankizumab prescription defined as:

  * Percentage of body surface affected by PsO Body Surface Area (BSA) \>2% and \<20%
  * Psoriasis Area and Severity Index (PASI) score \>10
  * Static Physician's Global Assessment (sPGA) score =3 (moderate) based on a 5-point scale (0-4)
* Participants naïve to advanced treatments (biologics, apremilast, and deucravacitinib)
* Participants who have been prescribed treatment with risankizumab in line with marketing authorization and local access conditions, prior to signed Informed Consent
* Decision to treat with risankizumab has been made independently and prior to enrolment in the study
* Participants must be willing and able to read and complete the study specific questionnaires

Exclusion Criteria:

* Participants who currently receive treatment with any investigational drug/device/intervention or who have received any investigational product within 30 days before risankizumab initiation
* Pregnancy or lactation
* Unwilling or unable to provide informed consent

Where this trial is running

Patras, Achaia and 20 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Moderate Plaque PsoriasisModerate PsoriasisPsoriasis
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.